Pivotal data cement use of Incyte, Novartis' ruxolitinib in difficult-to-treat graft-versus-host disease
Allogeneic stem-cell transplants, in which patients are given stem cells harvested from a donor to replenish depleted supplies caused by radiation treatment or high doses …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
